Eledon Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 20
- Market Cap
- $113.4M
- Website
- http://eledon.com
- Introduction
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody...
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Eledon Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT06126380
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸Virginia Commonwealth University, Richmond, Virginia, United States
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Eledon Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT05983770
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Eledon Pharmaceuticals
- Registration Number
- NCT05480657
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Eledon Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT05125068
- Locations
- 🇹🇭
Chulalongkorn University, Pathum Wan, Bangkok, Thailand
🇹🇭Prince of Songkla University, Dusit, Bangkok, Thailand
🇦🇺Monash Medical Centre, Clayton, Victoria, Australia
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Eledon Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT05027906
- Locations
- 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇨🇦Providence Health Care - St. Paul's Hospital, Vancouver, British Columbia, Canada